<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651089</url>
  </required_header>
  <id_info>
    <org_study_id>01-SP16</org_study_id>
    <nct_id>NCT03651089</nct_id>
  </id_info>
  <brief_title>SP16 SERPIN-like Peptide Administration in Healthy Individuals</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of a Single Intravenous Administration of SP16-a SERPIN-like, Small Peptide Agonist of the Low Density Lipoprotein-like Receptor 1-in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serpin Pharma, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Mason University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Serpin Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled Phase 1 Clinical Trial of 24
      healthy individuals to test the safety, tolerability and pharmacokinetics of a single
      subcutaneous administration of Serpin Peptide 16 (SP16), a Serine Protease Inhibitor
      (Serpin)-like, small peptide agonist of the Low Density Lipoprotein Receptor-like Protein 1
      (LRPP1) hypothesized to have anti-inflammatory activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the major determinants for outcome in patients with acute myocardial infarction (AMI)
      is the degree of inflammatory response. SP16 is a synthetic anti-inflammatory peptide
      developed to reproduce the anti-inflammatory activities of naturally occurring Serpins and
      has been tested as a treatment for AMI in mice. This Phase I trial will be the first to test
      the hypothesis that a single subcutaneous administration of SP16 is safe and well tolerated
      in healthy individuals, while also assessing the pharmacokinetic parameters of three
      different dosages. Participants will undergo direct clinical monitoring for up to 12 hours
      after drug administration. Additionally, participants will follow up with the same
      assessments at 24 hours, 48-72 hours and 7 days post drug administration.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study is set up as 3 sequential parallel studies, each testing a different drug dosage against placebo. In each dosing cohort, three patients (2 active and 1 placebo) will be randomized to receive a single study drug infusion on separate days, at least 24 hours apart. The remaining subjects in each dosing cohort (1 placebo and 4 active) will receive study drug after at least 24 hours from the 3rd subject.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preliminary Safety Assessment: Occurence of adverse events</measure>
    <time_frame>7 days follow-up</time_frame>
    <description>Occurence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of SP16 in healthy subjects</measure>
    <time_frame>7 days</time_frame>
    <description>Population estimate of volume of distribution will be calculated using non-compartmental analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of SP16 in healthy subjects</measure>
    <time_frame>7 days</time_frame>
    <description>Population estimate of clearance will be calculated using non-compartmental analysis</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>SP16 0.0125</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.0125 mg/kg of SP16 will be administered by subcutaneous injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP16 0.050</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.050 mg/kg of SP16 will be administered by subcutaneous injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP16 0.20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.20 mg/kg of SP16 will be administered by subcutaneous injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sterile saline) will be administered by subcutaneous injection once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP16</intervention_name>
    <description>subcutaneous injection of experimental anti-inflammatory drug</description>
    <arm_group_label>SP16 0.0125</arm_group_label>
    <arm_group_label>SP16 0.050</arm_group_label>
    <arm_group_label>SP16 0.20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>subcutaneous injection of sterile saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age 18 to 59 years

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

          -  Ability to take oral medication and be willing to adhere to the medication regimen

          -  For females of reproductive potential: Use of highly effective contraception

          -  For males of reproductive potential: Use of condoms

        Exclusion Criteria:

          -  Acute or chronic illness affecting organ function or requiring medications (including,
             but not limited to, cardiovascular, hepatic, renal hematologic, neurologic,
             dermatologic, psychiatric, or rheumatologic disease);

          -  Febrile illness within the previous 14 days;

          -  Known allergic reactions to components of the study agent;

          -  Treatment with another investigational drug or other intervention within 30 days;

          -  Current tobacco use or tobacco use within 60 days;

          -  Household contacts who are immunocompromised;

          -  Chronic infection(s) (of any kind);

          -  Malignancy (of any kind);

          -  Substance abuse disorder(s);

          -  Pregnancy or breastfeeding;

          -  Any other conditions that would place the subject at increased risk of adverse events
             or interfere with the conduct or interpretation of the study, in the opinion of the
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>January 13, 2019</last_update_submitted>
  <last_update_submitted_qc>January 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myocardial infarction</keyword>
  <keyword>inflammation</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or manuscript</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

